Vitamin K Dosing for Polytrauma with Hemopneumothorax and SAH (INR 2.3)
Administer vitamin K 10 mg IV immediately, along with 3-factor or 4-factor prothrombin complex concentrate (PCC) at 25 U/kg, given the presence of subarachnoid hemorrhage with an INR ≥ 1.4. 1
Rationale for Urgent Reversal
Your patient has intracranial hemorrhage (subarachnoid hemorrhage) with an elevated INR of 2.3, which meets the threshold (INR ≥ 1.4) for urgent reversal according to the Neurocritical Care Society and Society of Critical Care Medicine guidelines. The presence of concurrent hemopneumothorax in this polytrauma patient further amplifies bleeding risk and the need for rapid coagulopathy correction.
The guideline provides a strong recommendation for urgent reversal of vitamin K antagonists in patients with intracranial hemorrhage (strong recommendation, moderate quality evidence), emphasizing that rapid reversal may help limit hematoma expansion and improve outcomes. 1
Specific Dosing Protocol
Vitamin K Administration
- Dose: 10 mg IV (single dose) 1
- Timing: Administer as soon as possible or concomitantly with PCC 1
- Route: Intravenous (preferred over subcutaneous for rapid effect) 1
- Infusion rate: Not exceeding 1 mg per minute to minimize anaphylactic risk 2
Why 10 mg?
The European trauma guideline recommends 5-10 mg vitamin K because less than 5 mg may not fully correct the INR, while more than 10 mg can prevent re-warfarinization for days and may create a prothrombotic state. 3 The 10 mg dose ensures durable reversal with sustained effect beyond the 6-hour half-life of factor VII from PCC. 3
Concurrent PCC Administration
Do not give vitamin K alone in this scenario. The guidelines explicitly recommend PCC administration alongside vitamin K for INR ≥ 1.4 with intracranial hemorrhage:
- PCC dose: 25 U/kg (since INR is 2-4.0 range) 3
- Type: 4-factor PCC preferred over 3-factor PCC (lower thrombotic risk in trauma) 3
- Alternative: Fresh frozen plasma 10-15 mL/kg IV only if PCC unavailable 1
The PCC provides immediate factor replacement while vitamin K ensures sustained endogenous production of vitamin K-dependent clotting factors (II, VII, IX, X). 3
Follow-up Monitoring
- Recheck INR within 24-48 hours after initial reversal 1
- If INR remains ≥ 1.4: Redose with vitamin K 10 mg IV 1
- Monitor regularly over the next week: A minority of patients require additional vitamin K as warfarin clearance can take over a week 3
Critical Caveats
Anaphylactic Risk
Vitamin K IV carries a rare but serious risk of anaphylactic reaction (3 per 100,000 doses), possibly due to the solubilizer rather than vitamin K itself. 3 The slow infusion rate (≤1 mg/min) is mandatory. 2
Thromboprophylaxis Consideration
After bleeding is controlled, consider thromboprophylaxis as early as possible, as PCC use increases venous and arterial thrombosis risk during recovery. 3 This is particularly relevant in polytrauma patients with prolonged immobilization risk.
Route Preference
While the FDA label mentions subcutaneous administration 2, IV route is preferred in this emergency for rapid INR correction. Subcutaneous vitamin K is relatively ineffective and may cause overcorrection. 4